Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus Neubauer

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Lung Cancer (Amsterdam, Netherlands)|November 16, 2004
Results of a Phase II study of carboplatin plus gemcitabine in patients with untreated extensive small cell lung cancerMarcus Neubauer, Ralph Heaven, Jairo Olivares, et al.
Clinical Lung Cancer|October 10, 2007
Prognostic factors in stage III non-small-cell lung cancerFoluso O Ademuyiwa, Cynthia S Johnson, Angela S White, et al.
Cancer|February 8, 2007
A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancerLeena Gandhi, Matthew W Harding, Marcus Neubauer, et al.
American Journal of Clinical Oncology|April 26, 2003
Phase II study of MGI-114 administered intravenously for 5 days every 28 days to patients with metastatic colorectal cancerSunita Dwivedy Nasta, Paulo M Hoff, Christopher S George, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 13, 2018
Redefining Quality Measurement in Cancer CareElizabeth A Nardi, James McCanney, Katy Winckworth-Prejsnar, et al.
Journal of the National Cancer Institute|May 4, 2019
The Centers for Medicare & Medicaid Services Oncology Care Model Halfway Through: Perspectives from Diverse ParticipantsRonald M Kline, Michelle Brown, Nikolas Buescher, et al.
Clinical Breast Cancer|March 20, 2010
A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapyJohn Pippen, Anthony D Elias, Marcus Neubauer, et al.
Investigational New Drugs|September 22, 2010
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumorsMatthew D Galsky, Daniel D Von Hoff, Marcus Neubauer, et al.
The Lancet. Oncology|November 16, 2013
Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trialEdward S Kim, Marcus Neubauer, Allen Cohn, et al.
Clinical Lung Cancer|August 25, 2011
A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancerAlexander I Spira, Nicholas O Iannotti, Michael A Savin, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Lung Cancer (Amsterdam, Netherlands)|November 16, 2004
Results of a Phase II study of carboplatin plus gemcitabine in patients with untreated extensive small cell lung cancerMarcus Neubauer, Ralph Heaven, Jairo Olivares, et al.
Clinical Lung Cancer|October 10, 2007
Prognostic factors in stage III non-small-cell lung cancerFoluso O Ademuyiwa, Cynthia S Johnson, Angela S White, et al.
Cancer|February 8, 2007
A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancerLeena Gandhi, Matthew W Harding, Marcus Neubauer, et al.
American Journal of Clinical Oncology|April 26, 2003
Phase II study of MGI-114 administered intravenously for 5 days every 28 days to patients with metastatic colorectal cancerSunita Dwivedy Nasta, Paulo M Hoff, Christopher S George, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 13, 2018
Redefining Quality Measurement in Cancer CareElizabeth A Nardi, James McCanney, Katy Winckworth-Prejsnar, et al.
Journal of the National Cancer Institute|May 4, 2019
The Centers for Medicare & Medicaid Services Oncology Care Model Halfway Through: Perspectives from Diverse ParticipantsRonald M Kline, Michelle Brown, Nikolas Buescher, et al.
Clinical Breast Cancer|March 20, 2010
A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapyJohn Pippen, Anthony D Elias, Marcus Neubauer, et al.
Investigational New Drugs|September 22, 2010
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumorsMatthew D Galsky, Daniel D Von Hoff, Marcus Neubauer, et al.
The Lancet. Oncology|November 16, 2013
Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trialEdward S Kim, Marcus Neubauer, Allen Cohn, et al.
Clinical Lung Cancer|August 25, 2011
A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancerAlexander I Spira, Nicholas O Iannotti, Michael A Savin, et al.
Pageof 3